Logo

CareFirst BlueCross/Blue Shield to Cover Vermillion's OVA1

Aug 19, 2015 | staff reporter

NEW YORK (GenomeWeb) – Vermillion said today that CareFirst Blue Cross/Blue Shield has begun covering the company's OVA1 ovarian cancer test.

According to Vermillion, CareFirst is the largest insurer in Maryland, covering 3.4 million people, representing more than 40 percent of the state's population.

With the announcement, Vermillion now has commercial coverage for OVA1 for more than 16 million lives. The company received another positive coverage decision for the test in April from Blue Cross/Blue Shield of Michigan.

Filed under

Cancer
Proteomics & Protein Research
Molecular Diagnostics
Vermillion
Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.